Teladoc Health (TDOC)
(Delayed Data from NYSE)
$9.84 USD
+0.33 (3.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $9.88 +0.04 (0.41%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.84 USD
+0.33 (3.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $9.88 +0.04 (0.41%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth D Momentum A VGM
Zacks News
Teladoc (TDOC) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Teladoc (TDOC) earnings were aided by membership growth and increased visits.
Can Revenue Rise Aid Envision Healthcare (EVHC) Q4 Earnings?
by Zacks Equity Research
Envision Healthcare (EVHC) Q4 earnings might see an upside from higher revenues in Physician Services segment, partly offset by high expenses and lower revenues from Ambulatory Service segment.
Will Higher Revenues Buoy Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter 2017 results to benefit from an increase in members utilizing its services, higher visits and growing client roaster.
Will Lower Volume Hurt Tenet Healthcare's (THC) Q4 Earnings?
by Zacks Equity Research
Industry-wide softness in admissions might affect Tenet Healthcare's (THC) fourth-quarter results.
Teladoc Provides Strong Preliminary Results & 2018 Outlook
by Zacks Equity Research
Teladoc's (TDOC) impressive fourth-quarter preliminary results and 2018 guidance reflects the company's solid business growth.
Why Teladoc (TDOC) Is Up More Than 110% So Far This Year
by Zacks Equity Research
Teladoc (TDOC) stock seems to be favored by its rapidly growing revenue base and leadership position in underpenetrated telehealth services industry.
Teladoc, Inc. (TDOC) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Teladoc, Inc. (TDOC) was a big mover last session, as the company saw its shares nearly 11/% on the day amid huge volumes.
Teladoc Rides on Growing Demand for Telehealth Services
by Zacks Equity Research
Rising demand for telehealth services is likely to create long-term growth opportunities for Teladoc's (TDOC).
Teladoc (TDOC) Q3 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Teladoc's (TDOC) third-quarter revenues grew year over year on higher visits.
Will Increased Visits Drive Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) earnings will benefit from its premier consumer engagement capabilities, broad network and scalable platform, which will increase visits and clients.
Will High Costs Dent Envision Healthcare (EVHC) Q3 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) third-quarter earnings are likely to see a drag from high expenses, partly offset by increased revenues from its physician services segment.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
Will Higher Admissions Aid HCA Healthcare (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter earnings are likely to be benefited by its inorganic growth measures partly offset by industry weakness.
Can Admissions Rise Fuel Universal Health (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) third-quarter results are likely to be driven by solid revenue growth in both its Acute Care and Behavioral Health segments.
Can Enrollment Growth Drive Anthem (ANTM) in Q3 Earnings?
by Zacks Equity Research
Anthem's (ANTM) third-quarter results are likely to be aided by membership growth.
Can Medicaid Business Drive Centene's (CNC) Q3 Earnings?
by Zacks Equity Research
Centene's (CNC) third-quarter results are expected to be positively impacted by its Medicaid expansion initiatives.
Teladoc (TDOC) Looks Good: Stock Adds 6.8% in Session
by Zacks Equity Research
Teladoc (TDOC) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Why Is Teladoc (TDOC) Up 3.2% Since the Last Earnings Report?
by Zacks Equity Research
Teladoc (TDOC) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Teladoc (TDOC) Continues to Suffer From High Operating Cost
by Zacks Equity Research
Teladoc's (TDOC) high expenses continue to bother. Investment expenses undertaken for business growth offer no respite on this account.
Teladoc (TDOC) Q2 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Teladoc's (TDOC) second-quarter loss was wider than expected due to higher expenses.
Healthcare Q2 Earnings Due on Aug 2: HUM, PRXL, MOH, TDOC
by Zacks Equity Research
The Medical sector is likely to benefit from inorganic growth, product launches, technology upgrades. However, regulatory hassles might offset its growth potential.
Will Teladoc (TDOC) Pull Off a Surprise in Q2 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) second-quarter earnings may be driven by higher revenues and increased membership, partly offset by an increase in operating expenses.
Teladoc (TDOC) to Raise Debt for Best Doctors Acquisition
by Zacks Equity Research
Teladoc, Inc. (TDOC) announced recently that it would offer senior notes worth $200 million, with the year of maturity fixed as 2022.
Teladoc (TDOC) to Buy Best Doctors, Stock Hits New High
by Zacks Equity Research
Teladoc Inc. (TDOC) has inked a definitive agreement to acquire Best Doctors, a leader in medical consultation.
Teladoc (TDOC) Up 17% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.